The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung
Abstract
Purpose: To investigate the safety and pharmacokinetics of aerosolized Sustained Release Lipid Inhalation Targeting (SLIT) Cisplatin in patients with lung carcinoma. Experimental Design: Phase I, dose-escalating study of SLIT Cisplatin given in two sessions daily. Safety data, including laboratory variables, adverse events, pulmonary function tests, and radiographic imaging, were collected and analyzed for all patients to determine toxicity. Pharmacokinetic monitoring was done during the first course. Results: Seventeen patients and one tracheostomy patient on compassionate use received treatment. Aerosolized cisplatin was well tolerated. No dose-limiting toxicity was observed at the maximum delivered dose. Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or neurotoxicity. Most common adverse events were nausea (64.7%), vomiting (47.1%), dyspnea (64.7%), fatigue (64.7%), and hoarseness (47.1%). Pharmacokinetic data showed very low plasma platinum levels only with the longest repeated inhalations. Common Toxicity Criteria grade 2 decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide after one course occurred both in two patients and grade one decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide in six and five patients, respectively. Direct airway deposition via the tracheostomy resulted in clinical deterioration after two cycles best described as bronchitis, completely reversible within days. Overall response: stable disease in 12 patients and progressive disease in 4 patients (one patient received one cycle). Conclusions: Aerosolized liposomal cisplatin was found to be feasible and safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Abdelaziz, H. M., Gaber, M., Abd-Elwakil, M. M., Mabrouk, M. T., Elgohary, M. M., Kamel, N. M., Kabary, D. M., Freag, M. S., Samaha, M. W., Mortada, S. M., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.036 · Cited by 409
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 352
Mangal, S., Gao, W., Li, T., & Zhou, Q. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 288
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
Metadata
- Authors
- Wittgen, B. P. H., Kunst, P. W. A., van der Born, K., van Wijk, A. W., Perkins, W., Pilkiewicz, F. G., Perez-Soler, R., Nicholson, S., Peters, G. J., & Postmus, P. E.
- Venue
- Clinical Cancer Research
- Published
- 2007-04-15
- Volume
- 13
- Issue
- 8
- Pages
- 2414-2421
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149974395
- Cited by
- 166
- References
- 1
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-1480
- The paper
- Wittgen, B. P. H., Kunst, P. W. A., van der Born, K., van Wijk, A. W., Perkins, W., Pilkiewicz, F. G., Perez-Soler, R., Nicholson, S., Peters, G. J., & Postmus, P. E. (2007). Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-1480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.